LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 21

Search options

  1. Article ; Online: The clinical utility of a risk-modifying SNP to detect carriers for spinal muscular atrophy with increased sensitivity.

    Ware, Gardenier / Miller, Cecelia / Jones, Dan / Avenarius, Matthew

    Molecular genetics & genomic medicine

    2022  Volume 10, Issue 4, Page(s) e1897

    Abstract: Background: Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by biallelic inactivation of the survival motor neuron 1 (SMN1) gene. With a prevalence of ~1 in 11,000 live births (carrier frequency of ~1:50), SMA is one ... ...

    Abstract Background: Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by biallelic inactivation of the survival motor neuron 1 (SMN1) gene. With a prevalence of ~1 in 11,000 live births (carrier frequency of ~1:50), SMA is one of the most common severe childhood-onset diseases; therefore, current guidelines recommend pan-ethnic carrier screening for SMA before or during pregnancy. Routine SMN1 copy number assessment detects ~96% of all SMA carriers, but not the remaining 4% who harbor two copies of SMN1 arrayed in -cis [2 + 0]. The c.*3+80T>G risk-modifying SNP positively correlates with this chromosomal configuration and may be used to modify the residual risk of being a carrier for SMA.
    Methods: One year after incorporating the detection of the c.*3+80>G risk-modifying SNP into our routine SMA carrier screen, we perform a retrospective chart review to evaluate its frequency and utilization in the prenatal clinic.
    Results: In comparison with classic carriers for SMA, study data show that individuals with two copies of SMN1 and the risk modifier were counseled less frequently about their increased risk of being a carrier for SMA.
    Conclusion: Incorporating the c.*3+80T>G risk-modifying SNP is important for detecting carriers for SMA with a higher clinical sensitivity.
    MeSH term(s) Child ; Female ; Genetic Carrier Screening ; Genetic Counseling ; Humans ; Inheritance Patterns ; Muscular Atrophy, Spinal/diagnosis ; Muscular Atrophy, Spinal/genetics ; Pregnancy ; Retrospective Studies ; Survival of Motor Neuron 1 Protein/genetics
    Chemical Substances Survival of Motor Neuron 1 Protein
    Language English
    Publishing date 2022-03-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2734884-2
    ISSN 2324-9269 ; 2324-9269
    ISSN (online) 2324-9269
    ISSN 2324-9269
    DOI 10.1002/mgg3.1897
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Transformed Plasmablastic Lymphoma Presenting With Marked Lymphocytosis and Spontaneous Tumor Lysis Syndrome.

    Hadjiyannis, Yannis / Miller, Cecelia / Hollie, Norris I / Balakrishna, Jayalakshmi / Cottini, Francesca

    Journal of hematology

    2023  Volume 12, Issue 1, Page(s) 49–58

    Abstract: The clinicopathology entity of plasmablastic lymphoma (PBL), despite broad recognition by the World Health Organization (WHO), represents a diagnostic challenge due to its overlapping features and scarce occurrence. Often, PBL arises in immunodeficient, ... ...

    Abstract The clinicopathology entity of plasmablastic lymphoma (PBL), despite broad recognition by the World Health Organization (WHO), represents a diagnostic challenge due to its overlapping features and scarce occurrence. Often, PBL arises in immunodeficient, elderly male patients, most notably those who are human immunodeficiency virus (HIV)-positive. More infrequent, cases of transformed PBL (tPBL) evolved from another hematologic disease have been identified. Herein, we describe a case of a 65-year-old male transferred from a neighboring hospital with pronounced lymphocytosis and spontaneous tumor lysis syndrome (sTLS) presumed to be chronic lymphocytic leukemia (CLL). Utilizing a complete clinical, morphologic, immunophenotypic, and molecular evaluation, we arrived at a final diagnosis of tPBL with sTLS, suspected to have evolved from the
    Language English
    Publishing date 2023-02-25
    Publishing country Canada
    Document type Case Reports
    ZDB-ID 2662519-2
    ISSN 1927-1220 ; 1927-1220
    ISSN (online) 1927-1220
    ISSN 1927-1220
    DOI 10.14740/jh1067
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.

    Avenarius, Matthew R / Huang, Ying / Kittai, Adam S / Bhat, Seema A / Rogers, Kerry A / Grever, Michael R / Woyach, Jennifer A / Miller, Cecelia R

    Leukemia

    2024  Volume 38, Issue 3, Page(s) 676–678

    MeSH term(s) Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Karyotyping ; Karyotype
    Language English
    Publishing date 2024-02-19
    Publishing country England
    Document type Letter
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-024-02177-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Culture and Harvest of CpG-Stimulated Peripheral Blood or Bone Marrow in Chronic Lymphocytic Leukemia.

    Miller, Cecelia R / Heerema, Nyla A

    Methods in molecular biology (Clifton, N.J.)

    2018  Volume 1881, Page(s) 27–34

    Abstract: Chromosome analysis of chronic lymphocytic leukemia (CLL) is an important clinical tool for evaluating prognosis and disease progression. Visualizing chromosomes microscopically using traditional cytogenetic techniques requires dividing cells to be ... ...

    Abstract Chromosome analysis of chronic lymphocytic leukemia (CLL) is an important clinical tool for evaluating prognosis and disease progression. Visualizing chromosomes microscopically using traditional cytogenetic techniques requires dividing cells to be arrested during metaphase. The major challenge for performing this analysis on CLL samples is stimulating the cells to divide in culture. Stimulation of CLL cells with CpG oligodeoxynucleotides has improved our ability to perform chromosome analysis for this leukemia. This protocol should help the reader successfully culture CLL samples for clinical chromosome analysis.
    MeSH term(s) B-Lymphocytes/drug effects ; Bone Marrow Cells/drug effects ; Humans ; Karyotyping/instrumentation ; Karyotyping/methods ; Leukemia, Lymphocytic, Chronic, B-Cell/blood ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Metaphase/drug effects ; Mitogens/pharmacology ; Oligodeoxyribonucleotides/pharmacology ; Primary Cell Culture/instrumentation ; Primary Cell Culture/methods ; Specimen Handling/instrumentation ; Specimen Handling/methods ; Tumor Cells, Cultured
    Chemical Substances CPG-oligonucleotide ; GNKG168 ; Mitogens ; Oligodeoxyribonucleotides
    Language English
    Publishing date 2018-10-22
    Publishing country United States
    Document type Journal Article
    ISSN 1940-6029
    ISSN (online) 1940-6029
    DOI 10.1007/978-1-4939-8876-1_3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma.

    Ozga, Michael / Zhao, Qiuhong / Huric, Laila / Miller, Cecelia / Rosko, Ashley / Khan, Abdullah / Umyarova, Elvira / Benson, Don / Cottini, Francesca

    Blood cancer journal

    2023  Volume 13, Issue 1, Page(s) 167

    MeSH term(s) Humans ; Multiple Myeloma/diagnosis ; Multiple Myeloma/genetics ; Prognosis ; Immune System ; Chromosome Aberrations
    Language English
    Publishing date 2023-11-10
    Publishing country United States
    Document type Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-023-00943-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization.

    Teierle, Samantha M / Huang, Ying / Kittai, Adam S / Bhat, Seema A / Grever, Michael / Rogers, Kerry A / Zhao, Weiqiang / Jones, Daniel / Byrd, John C / Avenarius, Matthew R / Heerema, Nyla A / Woyach, Jennifer A / Miller, Cecelia R

    Blood advances

    2023  Volume 7, Issue 23, Page(s) 7239–7242

    MeSH term(s) Humans ; In Situ Hybridization, Fluorescence ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Chromosome Deletion ; Gene Deletion ; Cyclin-Dependent Kinase Inhibitor p16/genetics
    Chemical Substances CDKN2A protein, human ; Cyclin-Dependent Kinase Inhibitor p16
    Language English
    Publishing date 2023-10-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2023010753
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results.

    Avenarius, Matthew R / Huang, Ying / Hyak, Jonathan / Byrd, John C / Bhat, Seema A / Grever, Michael / Kittai, Adam S / Rogers, Kerry A / Jones, Dan / Zhao, Weiqiang / Heerema, Nyla A / Abruzzo, Lynne V / Woyach, Jennifer / Miller, Cecelia R

    Hematological oncology

    2023  Volume 41, Issue 4, Page(s) 771–775

    Abstract: Fluorescence in situ hybridization (FISH) to detect the recurrent cytogenetics abnormalities deletion 13q, trisomy 12, deletion 11q, and deletion 17p is important for prognostication in chronic lymphocytic leukemia (CLL). A subset of patients are ... ...

    Abstract Fluorescence in situ hybridization (FISH) to detect the recurrent cytogenetics abnormalities deletion 13q, trisomy 12, deletion 11q, and deletion 17p is important for prognostication in chronic lymphocytic leukemia (CLL). A subset of patients are negative for each of these abnormalities (normal 12/13/11/17 FISH), and outcomes are heterogenous within this group. To elucidate variables important for prognostication in this subgroup we conducted a retrospective analysis of 280 treatment-naïve CLL patients with normal standard CLL FISH results. In a multivariable model, advanced Rai stage (p = 0.04, hazard ratio [HR] 1.24 (95% confidence interval [CI] 1.01-1.53)), unmutated immunoglobulin heavy chain gene (IGHV) (p < 0.0001, HR 5.59 (95% CI 3.63-8.62)) and IGH rearrangement by FISH (p = 0.02, HR 2.56 (95% CI 1.20-5.48)) were significantly associated with shorter time to first treatment. In a multivariable model for overall survival, increasing age at 5-year increments (p < 0.0001, HR 1.55 (95% CI 1.25-1.93)), unmutated IGHV (p = 0.01, HR 5.28 (95% CI 1.52-18.35)) and gain of REL (p = 0.01, HR 4.08 (5% CI 1.45-11.49)) were significantly associated with shorter survival. Our study identifies variables important for refining prognosis for CLL patients with normal standard CLL FISH results.
    MeSH term(s) Humans ; Child, Preschool ; In Situ Hybridization, Fluorescence/methods ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Retrospective Studies ; Chromosome Aberrations ; Prognosis
    Language English
    Publishing date 2023-04-03
    Publishing country England
    Document type Letter
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.3134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes.

    Hyak, Jonathan M / Huang, Ying / Rogers, Kerry A / Bhat, Seema A / Grever, Michael R / Byrd, John C / Kittai, Adam S / Jones, Dan / Miller, Cecelia R / Woyach, Jennifer A

    Blood advances

    2022  Volume 6, Issue 17, Page(s) 5124–5127

    MeSH term(s) Agammaglobulinaemia Tyrosine Kinase ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Proto-Oncogene Proteins c-bcl-2 ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use
    Chemical Substances BCL2 protein, human ; Proto-Oncogene Proteins c-bcl-2 ; Pyrimidines ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2)
    Language English
    Publishing date 2022-07-09
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2022007708
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.

    Kittai, Adam S / Huang, Ying / Beckwith, Kyle A / Bhat, Seema A / Bond, David A / Byrd, John C / Goldstein, Daniel / Grever, Michael R / Miller, Cecelia / Rogers, Kerry A / Yano, Max / Woyach, Jennifer A

    American journal of hematology

    2022  Volume 98, Issue 1, Page(s) 56–65

    Abstract: Chronic lymphocytic leukemia (CLL) transformation to aggressive lymphoma, known as Richter's Transformation (RT), has a dismal prognosis. There are limited data evaluating risk of RT in patients treated with ibrutinib. We performed a retrospective ... ...

    Abstract Chronic lymphocytic leukemia (CLL) transformation to aggressive lymphoma, known as Richter's Transformation (RT), has a dismal prognosis. There are limited data evaluating risk of RT in patients treated with ibrutinib. We performed a retrospective analysis to determine prognostic variables associated with development of RT and overall survival (OS) at progression after treatment with ibrutinib. We identified 559 patients with CLL treated with ibrutinib from 2010-2019. After a median follow-up of 44.5 months from ibrutinib start, 179 patients progressed and were included in our analysis. After a median follow-up of 20.8 months from progression, 54 out of 179 patients developed RT. Progression on treatment (hazard ratio [HR] 4.01 [1.60-10.00], p = .003), higher LDH (HR 1.80 for 2-fold increase [1.33-2.43], p = .0001), and lymphadenopathy without lymphocytosis (HR 2.88 [1.15-7.20], p = .02) were independent prognostic variables for the development of RT at progression. Progression with lymphadenopathy without lymphocytosis continued to be an independent prognostic variable of worse OS post-progression. In a subset analysis of 50 patients who obtained a PET-CT at progression, the median SUV
    MeSH term(s) Humans ; Leukemia, Lymphocytic, Chronic, B-Cell ; Positron Emission Tomography Computed Tomography ; Retrospective Studies ; Lymphocytosis ; Lymphoma, Large B-Cell, Diffuse ; Lymphadenopathy
    Chemical Substances ibrutinib (1X70OSD4VX)
    Language English
    Publishing date 2022-10-20
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26755
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.

    Kittai, Adam S / Bond, David / Huang, Ying / Bhat, Seema A / Blyth, Emily / Byrd, John C / Chavez, Julio C / Davids, Matthew S / Dela Cruz, Jamie P / Dowling, Mark R / Duffy, Caitlyn / Ho, Carrie / Jacobson, Caron / Jaglowski, Samantha / Jain, Nitin / Lin, Kevin H / Miller, Cecelia / McCarthy, Christine / Omer, Zulfa /
    Parry, Erin / Rai, Manoj / Rogers, Kerry A / Saha, Aditi / Schachter, Levanto / Scott, Hamish / Senapati, Jayastu / Shadman, Mazyar / Siddiqi, Tanya / Stephens, Deborah M / Vanguru, Vinay / Wierda, William / Woyach, Jennifer A / Thompson, Philip A

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2024  , Page(s) JCO2400033

    Abstract: Purpose: Outcomes for Richter transformation (RT) are poor with current therapies. The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for RT are not established.: Methods: We performed an international multicenter ... ...

    Abstract Purpose: Outcomes for Richter transformation (RT) are poor with current therapies. The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for RT are not established.
    Methods: We performed an international multicenter retrospective study of patients with RT who received CAR-T. Patient, disease, and treatment characteristics were summarized using descriptive statistics, and modeling analyses were used to determine association with progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated from the date of CAR-T infusion.
    Results: Sixty-nine patients were identified. The median age at CAR-T infusion was 64 years (range, 27-80). Patients had a median of four (range, 1-15) previous lines of therapy for CLL and/or RT, including previous Bruton tyrosine kinase inhibitor and/or BCL2 inhibitor therapy in 58 (84%) patients. The CAR-T product administered was axicabtagene ciloleucel in 44 patients (64%), tisagenlecleucel in 17 patients (25%), lisocabtagene maraleucel in seven patients (10%), and brexucabtagene autoleucel in one patient (1%). Eleven patients (16%) and 25 patients (37%) experienced grade ≥3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, respectively. The overall response rate was 63%, with 46% attaining a complete response (CR). After a median follow-up of 24 months, the median PFS was 4.7 months (95% CI, 2.0 to 6.9); the 2-year PFS was 29% (95% CI, 18 to 41). The median OS was 8.5 months (95% CI, 5.1 to 25.4); the 2-year OS was 38% (95% CI, 26 to 50). The median duration of response was 27.6 months (95% CI, 14.5 to not reached) for patients achieving CR.
    Conclusion: CAR-T demonstrates clinical efficacy for patients with RT.
    Language English
    Publishing date 2024-03-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.24.00033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top